Bruce Robinson
Follow
Get notifications in MyBN when activity occurs.
Bruce Robinson
Non-Executive Director / Cochlear
Professor Bruce Robinson AC AM has over 20 years of leadership experience as an academic physician and scientist across research, healthcare and medicine, and tertiary education sectors.
He was a former Dean at the University of Sydney's Sydney Medical School, head of medicine at Sydney's Royal North Shore Hospital, and head of the Cancer Genetics Laboratory at the Kolling Institute for Medical Research.
Prof Robinson is also chair of National Health and Medical Research Council and Medical Benefits Schedule Review Taskforce, and a director of MaynePharma and QBiotics.
In 2012, Prof Robinson was awarded a Member of the Order of Australia. In 2020, he was one of only five people to be appointed a Companion of the Order of Australia for services to medical research, and to national healthcare, through policy development and reform, and to tertiary education.
He was a former Dean at the University of Sydney's Sydney Medical School, head of medicine at Sydney's Royal North Shore Hospital, and head of the Cancer Genetics Laboratory at the Kolling Institute for Medical Research.
Prof Robinson is also chair of National Health and Medical Research Council and Medical Benefits Schedule Review Taskforce, and a director of MaynePharma and QBiotics.
In 2012, Prof Robinson was awarded a Member of the Order of Australia. In 2020, he was one of only five people to be appointed a Companion of the Order of Australia for services to medical research, and to national healthcare, through policy development and reform, and to tertiary education.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 173rd | Cochlear | 60% | 17% |
| 280th | Collins Foods | 36% | 14% |
| 787th | Kelsian Group | -4% | 12% |
| 823rd | Accent Group | -6% | 13% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 99th |  | Cochlear | $1,949.6m |
| 126th | | Kelsian Group | $1,431.3m |
| 127th | | Accent Group | $1,420.7m |
| 130th | | Costa Group Holdings | $1,357.6m |
| 131st | | Collins Foods | $1,353.6m |
1328 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEW ROLE: Non-Executive Director, Ecofibre | 13 Apr 2022 |
| REMUNERATION UPDATE: Non-Executive Director, Mayne Pharma Group | 13 Nov 2020 |
| NEW ROLE: Non-Executive Director, Mayne Pharma Group | 03 Nov 2020 |
| NEW ROLE: Non-Executive Director, Cochlear | 03 Nov 2020 |
